The small molecule KHS101 induces bioenergetic dysfunction in glioblastoma cells through inhibition of mitochondrial HSPD1

Pharmacological inhibition of uncontrolled cell growth with small molecule inhibitors is a potential strategy against glioblastoma multiforme (GBM), the most malignant primary brain cancer. Phenotypic profiling of the neurogenic small molecule KHS101 revealed the chemical induction of lethal cellular degradation in molecularly-diverse GBM cells, independent of their tumor subtype, whereas non-cancerous brain cells remained viable. Mechanism-of-action (MOA) studies showed that KHS101 specifically bound and inhibited the mitochondrial chaperone HSPD1. In GBM but not non-cancerous brain cells, KHS101 elicited the aggregation of an enzymatic network that regulates energy metabolism. Compromised glycolysis and oxidative phosphorylation (OXPHOS) resulted in the metabolic energy depletion in KHS101-treated GBM cells. Consistently, KHS101 induced key mitochondrial unfolded protein response factor DDIT3 in vitro and in vivo, and significantly reduced intracranial GBM xenograft tumor growth upon systemic administration, without discernible side effects. These findings suggest targeting of HSPD1-dependent oncometabolic pathways as an anti-GBM therapy.

[1]  M. Prunotto,et al.  Opportunities and challenges in phenotypic drug discovery: an industry perspective , 2017, Nature Reviews Drug Discovery.

[2]  W. Kaelin,et al.  Common pitfalls in preclinical cancer target validation , 2017, Nature Reviews Cancer.

[3]  O. Werz,et al.  Mitochondrial Chaperonin HSP60 Is the Apoptosis-Related Target for Myrtucommulone. , 2017, Cell chemical biology.

[4]  M. Haigis,et al.  Mitochondria and Cancer , 2016, Cell.

[5]  M. Luo,et al.  Down-regulation of HSP60 Suppresses the Proliferation of Glioblastoma Cells via the ROS/AMPK/mTOR Pathway , 2016, Scientific Reports.

[6]  Stuart L Schreiber,et al.  The Power of Sophisticated Phenotypic Screening and Modern Mechanism-of-Action Methods. , 2016, Cell chemical biology.

[7]  J. Dick,et al.  MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. , 2015, Cancer Cell.

[8]  Douglas Hanahan,et al.  Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits Cell-Lethal Autophagy and Therapeutic Benefit. , 2015, Cancer cell.

[9]  M. Graner.  The unfolded protein response in glioblastomas: targetable or trouble? , 2015, Future science OA.

[10]  Fabian J Theis,et al.  Computational analysis of cell-to-cell heterogeneity in single-cell RNA-sequencing data reveals hidden subpopulations of cells , 2015, Nature Biotechnology.

[11]  Min Wu,et al.  Rapid Analysis of Glycolytic and Oxidative Substrate Flux of Cancer Cells in a Microplate , 2014, PloS one.

[12]  C. Wahlestedt,et al.  Emerging treatment strategies for glioblastoma multiforme , 2014, EMBO molecular medicine.

[13]  M. S. Fernández-García,et al.  ATP-dependent Lon protease controls tumor bioenergetics by reprogramming mitochondrial activity. , 2014, Cell reports.

[14]  Shawn M. Gillespie,et al.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.

[15]  A. IJzerman,et al.  Agonists for the adenosine A1 receptor with tunable residence time. A Case for nonribose 4-amino-6-aryl-5-cyano-2-thiopyrimidines. , 2014, Journal of medicinal chemistry.

[16]  Simon Kasif,et al.  Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells , 2014, Cell.

[17]  M. Tyers,et al.  BoxPlotR: a web tool for generation of box plots , 2014, Nature Methods.

[18]  K. Gardner,et al.  Regulating the ARNT/TACC3 axis: multiple approaches to manipulating protein/protein interactions with small molecules. , 2013, ACS chemical biology.

[19]  L. Soroceanu,et al.  Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. , 2013, Cancer research.

[20]  Reid C Thompson,et al.  Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma , 2013, Clinical Cancer Research.

[21]  William A. Flavahan,et al.  Glioma stem cell maintenance: the role of the microenvironment. , 2011, Current pharmaceutical design.

[22]  J. Stamler,et al.  Glioma Stem Cell Proliferation and Tumor Growth Are Promoted by Nitric Oxide Synthase-2 , 2011, Cell.

[23]  R. Stupp,et al.  Current concepts and management of glioblastoma , 2011, Annals of neurology.

[24]  W. Cavenee,et al.  Heterogeneity maintenance in glioblastoma: a social network. , 2011, Cancer research.

[25]  A. Ross,et al.  Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. , 2011, The Journal of clinical investigation.

[26]  P. Schultz,et al.  A small molecule accelerates neuronal differentiation in the adult rat , 2010, Proceedings of the National Academy of Sciences.

[27]  C. Eberhart,et al.  Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. , 2010, The American journal of pathology.

[28]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[29]  Peter G Schultz,et al.  An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation. , 2010, Cell stem cell.

[30]  J. Griffin,et al.  Metabolic phenotyping of a model of adipocyte differentiation. , 2009, Physiological genomics.

[31]  Subha Madhavan,et al.  Rembrandt: Helping Personalized Medicine Become a Reality through Integrative Translational Research , 2009, Molecular Cancer Research.

[32]  B. Cravatt,et al.  Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes. , 2008, Journal of the American Chemical Society.

[33]  William A Weiss,et al.  Recognizing and exploiting differences between RNAi and small-molecule inhibitors. , 2007, Nature chemical biology.

[34]  G. Riggins,et al.  A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII , 2007, Molecular Cancer.

[35]  G. Broggi,et al.  Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells , 2006, Nature.

[36]  R. Tibshirani,et al.  Missing value estimation methods for DNA microarrays , 2001, Bioinform..

[37]  C. Fokunang,et al.  Heterocycles 26: synthesis, characterisation, and anticancer activity of some thiazolic chalcones , 2014, Medicinal Chemistry Research.

[38]  O. Werz,et al.  Myrtucommulone from Myrtus communis induces apoptosis in cancer cells via the mitochondrial pathway involving caspase-9 , 2007, Apoptosis.

[39]  C. Giordano,et al.  Identi fi cation and Characterization of a Small-Molecule Inhibitor of Wnt Signaling in Glioblastoma Cells , 2022 .